MedImmune at outperform by Bear Stearns

Bear Stearns analyst Mark Schoenebaum upgraded MedImmune Inc. to outperform from peer perform on valuation and the near-term catalyst of HPV vaccine approval. The analyst established a price target of $35. Shares of the Gaithersburg, Md., biotechnology company were up $1.32, or 4.53%, at $30.47 on volume of 7,184,293 shares versus the three-month running average of 2,270,000 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.